Patents Represented by Attorney Wayne A. Keown

Find this attorney in the Justia Lawyer Directory

  • Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
    Patent number: 7833538
    Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: November 16, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
  • Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
    Patent number: 7790168
    Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: September 7, 2010
    Assignee: Idera Pharmaceuticals, Inc
    Inventors: Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
  • Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
    Patent number: 7776834
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunostimulatory oligonucleotides according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: August 17, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Dong Yu, Ekambar Kandimalla
  • Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
    Patent number: 7329648
    Abstract: The invention provides methods for modulating the immune response caused by CpG-containing oligonucleotides. The methods according to the invention enable both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: February 12, 2008
    Assignee: Idera Pharmacetuicals, Inc.
    Inventor: Sudhir Agrawal
  • Method for efficient and highly selective control of microorganisms
    Patent number: 6440409
    Abstract: The invention features a method of selectively killing a first microorganism. The method includes: (i) contacting the first microorganism with a second microorganism that has a microcidal compound; and (ii) allowing the first microorganism and the second microorganism to undergo fusion, whereby the microcidal compound is delivered into and kills the microorganism that forms following the fusion.
    Type: Grant
    Filed: April 16, 1999
    Date of Patent: August 27, 2002
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: G. Todd Milne, Gerald R. Fink
  • Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
    Patent number: 6426334
    Abstract: The invention provides new methods for modulating specific CMI-inducing cytokines in vivo. Such new methods result in stimulation of the cytokines IL-6, IL-12 MIP-1&bgr; and MCP without substantially inducing undesired cytokines. The methods according to the invention are based upon administration of oligonucleotides containing particular structural motifs which lead to specific cytokine induction.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: July 30, 2002
    Assignee: Hybridon, Inc.
    Inventors: Sudhir Agrawal, Qiuyan Zhao
  • Cosmetic compositions comprising exfoliating enzymes and uses thereof
    Patent number: 6416769
    Abstract: Cosmetic compositions for topical use that comprise an exfoliating enzyme for use in removal of at least a portion of the dead skin cells from the outer layer of skin, in conjunction with one or more botanicals, the delivery of which to subsurface layers and cells thereof of the skin is enhanced by the presence of the exfoliating enzyme. These compositions, including gels, lotions, and creams, are gentle, non-irritating and enhance the penetration of biological additives into the subsurface skin layers relative to currently commercially available compositions.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: July 9, 2002
    Assignee: Australian Importers, Ltd.
    Inventor: Jacob Vromen